The US Food and Drug Administration (FDA) has granted United States-based Dermira fast track designation for its lebrikizumab intended for the treatment of moderate-to-severe atopic dermatitis, it was reported yesterday.
According to the company, the product is a monoclonal antibody that can bind with very high affinity with the Interleukin 13 (IL-13) cykotine. Through this mechanism, the antibody is said to specifically inhibit the formation of the IL-13R alpha 1/IL-4R alpha heterodimer complex and subsequent signalling to block the biological effects of IL-13 in a targeted and efficient manner. The investigational drug was previously evaluated in two phase 2 clinical trials – TREBLE and ARBAN.
In the TREBLE study, the IL-13 inhibitor was assessed for its safety and efficacy in combination with topical corticosteroids, while the ARBAN study evaluated it as a monotherapy. Dermira said that in both the mid-stage studies, data suggested clinical improvements in patients treated with the IL-13 inhibitor.
Dermira chairman and CEO Tom Wiggans said, 'We are pleased that the FDA granted lebrikizumab its Fast Track designation and recognises the unmet need for patients living with moderate-to-severe atopic dermatitis and the potential for lebrikizumab to offer a treatment for this serious condition. This Fast Track designation puts us one step closer to potentially delivering a new therapeutic option more quickly to patients should the results from earlier Phase 2 studies be confirmed in the ongoing Phase 3 studies assessing the safety, efficacy and tolerability of the investigational therapy.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT